IVA

Inventiva

2.35 USD
-0.02
0.84%
At close Dec 20, 4:00 PM EST
1 day
-0.84%
5 days
-4.08%
1 month
-14.23%
3 months
14.63%
6 months
-19.24%
Year to date
-49.89%
1 year
-44.05%
5 years
-82.49%
10 years
-82.49%
 

About: Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Employees: 123

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.01% more ownership

Funds ownership: 9.24% [Q2] → 9.24% (+0.01%) [Q3]

0% more funds holding

Funds holding: 7 [Q2] → 7 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

37% less capital invested

Capital invested by funds: $14.5M [Q2] → $9.06M (-$5.41M) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
28%
upside
Avg. target
$11
368%
upside
High target
$17
623%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Stifel
Annabel Samimy
33% 1-year accuracy
4 / 12 met price target
623%upside
$17
Buy
Maintained
22 Nov 2024
UBS
Eliana Merle
20% 1-year accuracy
3 / 15 met price target
28%upside
$3
Neutral
Initiated
12 Nov 2024
HC Wainwright & Co.
Ed Arce
54% 1-year accuracy
79 / 146 met price target
453%upside
$13
Buy
Maintained
15 Oct 2024

Financial journalist opinion

Based on 3 articles about IVA published over the past 30 days

Neutral
GlobeNewsWire
5 days ago
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, has been invited to present a corporate overview, and will engage, with Inventiva's leadership team, in investor meetings at the upcoming 43rd Annual J.P. Morgan Annual Healthcare Conference, being held on January 13-16, 2025 at the Westin St. Francis in San Francisco, California.
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
Neutral
GlobeNewsWire
6 days ago
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that, following the general meeting of the shareholders held on December 11, 2024 (the “General Meeting”), the Board of Directors decided to use the delegations granted by the General Meeting to issue the second phase of Tranche 1 (the “T1 bis Transaction”) for a gross amount of €21.4 million (net amount of €20.1 million) of the multi-tranche equity financing of up to €348 million announced on October 14, 2024 (the “Multi-Tranche Financing”).
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Neutral
GlobeNewsWire
1 week ago
Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024
Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders' Meeting.
Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024
Neutral
GlobeNewsWire
1 month ago
Inventiva reports 2024 Third Quarter Financial Information¹
Daix (France), New York City, (New York, United States), November 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today reported its cash position as of September 30, 2024 and its revenues for the first nine months of 2024.
Inventiva reports 2024 Third Quarter Financial Information¹
Neutral
GlobeNewsWire
1 month ago
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of December 11, 2024.
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Neutral
Business Wire
1 month ago
Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams
CHICAGO--(BUSINESS WIRE)--Alight is integrating Alight Worklife® with Microsoft Teams, enabling seamless access to benefits and wellbeing info within the Teams platform.
Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams
Neutral
GlobeNewsWire
1 month ago
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the presentation of the final analysis of LEGEND, Phase 2 proof-of-concept clinical trial, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type 2 Diabetes (T2D). The data will be presented Monday November 18, 2024, as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in San Diego California.
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Neutral
GlobeNewsWire
1 month ago
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Daix (France), Long Island City (New York, United States), November 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the positive recommendation from the fifth scheduled meeting of the Data Monitoring Committee (“DMC”) to continue the NATiV3 Phase 3 clinical trial evaluating lanifibranor in patients with MASH without modification to the current trial protocol.
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Neutral
GlobeNewsWire
2 months ago
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), today announced that the results of the Phase 2, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type-2-Diabetes (“T2D”) has been accepted as late breaker by the scientific committee of the upcoming 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 being held November 15 to 19, 2024 in San Diego, California.
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Neutral
GlobeNewsWire
2 months ago
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announces that the Autorité des marchés financiers (the “AMF”) has approved a prospectus under no. 24-432, on October 14, 2024, in connection with its financing through the issuance of ordinary shares and pre-funded share warrants
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Charts implemented using Lightweight Charts™